Analysts See $0.04 EPS for Knight Therapeutics Inc. (GUD)

February 20, 2018 - By Linda Rogers

 Analysts See $0.04 EPS for Knight Therapeutics Inc. (GUD)

Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.04 EPS on March, 15.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $0.06 EPS. T_GUD’s profit would be $5.72 million giving it 48.25 P/E if the $0.04 EPS is correct. After having $0.03 EPS previously, Knight Therapeutics Inc.’s analysts see 33.33 % EPS growth. The stock increased 1.18% or $0.09 during the last trading session, reaching $7.72. About 94,780 shares traded. Knight Therapeutics Inc. (TSE:GUD) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Knight Therapeutics Inc. (TSE:GUD) Ratings Coverage

Among 2 analysts covering Knight Therapeutics (TSE:GUD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Knight Therapeutics had 11 analyst reports since May 12, 2016 according to SRatingsIntel. The stock of Knight Therapeutics Inc. (TSE:GUD) earned “Buy” rating by TD Securities on Friday, March 17.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company has market cap of $1.10 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. It has a 61.76 P/E ratio. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

More notable recent Knight Therapeutics Inc. (TSE:GUD) news were published by: which released: “Knight Therapeutics and SIFI SpA Announce Filing of New Drug Submission for …” on February 15, 2018, also with their article: “Knight Therapeutics (KHTRF) CEO Jonathan Ross Goodman on Q2 2017 Results …” published on August 10, 2017, published: “Knight Therapeutics’ (KHTRF) CEO Jonathan Ross Goodman on Q4 2015 Results …” on March 24, 2016. More interesting news about Knight Therapeutics Inc. (TSE:GUD) were released by: and their article: “Knight Announces Changing of the Finance Guard” published on October 10, 2017 as well as‘s news article titled: “How Many Times Can Knight Therapeutics Issue Equity?” with publication date: September 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: